Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nespecabtagene autoleucel
- Development stage
- Phase 2
- Lead developer
- AbClon
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Nespecabtagene autoleucel is a Chimeric Antigen Receptor (CAR) T-cell therapy developed by AbClon. It involves genetically modifying a patient's own T cells to express a CAR that specifically targets the CD19 protein found on B-cells. This re-directs the patient's immune system to recognize and eliminate CD19-expressing cancer cells. Unlike some other CD19-targeted CAR T-cell therapies, nespecabtagene autoleucel utilizes a distinct binding mechanism to target CD19 via a novel antibody (h1218), aiming to enhance efficacy and persistence. It is currently in development for the treatment of B-cell non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Other names
- nespe-cel
02
Targets
Beyond the preview
Go deeper on nespecabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nespecabtagene autoleucel.